In conclusion, the combination therapy of an AURKA inhibitor (MK-5108) and a MEK inhibitor (trametinib) exerts a synergistic antitumor effect on colon cancer cells regardless of TP53 and RAS/RAF mutation status via suppression of cell division by promotion of cell cycle arrest. This evidence concerns the gene MAP2K7 and colonic neoplasm.